首页> 美国卫生研究院文献>Disease Markers >Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas
【2h】

Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas

机译:PD-1在B细胞淋巴瘤中的诊断和预后作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aims: Programmed death-1 (PD-1) is expressed by germinal center-associated helper T-cells and acts as a negative regulator of the immune system. PD-1 is encountered on tumor cells of angioimmunoblastic T-cell lymphoma and is a postulated diagnostic marker in chronic lymphocytic leukemia (CLL/SLL). Recent data suggest prognostic importance of PD-1 in follicular lymphoma (FL). We assessed the diagnostic potential and the prognostic importance of PD-1 in B-cell lymphomas. Methods: Distribution of PD-1+ lymphocytes in B-cell lymphomas was studied on 403 cases. Correlation with known biologic and clinical key data was performed. Prognostic cut-off scores were determined by receiver operating curve analysis. Results: PD-1+ tumor-infiltrating lymphocytes were numerous in extranodal marginal zone lymphomas and FL. Their amount decreased from FL grade 1 to grade 3 and to FL with transformation to diffuse large B-cell lymphoma. An increased amount of PD-1 tumor-infiltrating lymphocytes above the prognostic cut-off score (> 2.8%) was a positive prognostic factor of disease-specific survival (DSS) in FL-patients. Five percent of the studied 66 CLL/SLL cases showed unequivocal PD-1 positivity of neoplastic cells. Conclusions: Increased number of PD-1+ tumor-infiltrating lymphocytes is associated with significantly improved DSS in FL and may be useful to predict its heterogeneous clinical behavior. PD-1 has probably limited diagnostic value for primary histopathological CLL/SLL diagnostics.
机译:目的:程序性死亡1(PD-1)由生发中心相关的辅助性T细胞表达,并充当免疫系统的负调节剂。 PD-1在血管免疫母细胞性T细胞淋巴瘤的肿瘤细胞上遇到,并且是慢性淋巴细胞性白血病(CLL / SLL)的假定诊断标记。最近的数据表明PD-1在滤泡性淋巴瘤(FL)中的预后重要性。我们评估了PD-1在B细胞淋巴瘤中的诊断潜力和预后重要性。方法:研究403例B细胞淋巴瘤中PD-1 +淋巴细胞的分布。与已知的生物学和临床关键数据进行了相关。通过接受者工作曲线分析确定预后截止评分。结果:结外边缘区淋巴瘤和FL中PD-1 +肿瘤浸润淋巴细胞很多。它们的数量从1级FL降低到3级,并随着转化为弥漫性大B细胞淋巴瘤而降至FL。在FL患者中,PD-1肿瘤浸润淋巴细胞的增加量超过预后临界值(> 2.8%)是疾病特异性生存(DSS)的积极预后因素。在所研究的66例CLL / SLL病例中,有5%显示出肿瘤细胞的PD-1阳性。结论:PD-1 +肿瘤浸润淋巴细胞数量增加与FL中DSS的显着改善有关,可能有助于预测其异质性临床行为。 PD-1对原发性组织病理学CLL / SLL诊断的诊断价值可能有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号